CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Quadruplet Therapy and Early-Line CAR T-Cell Therapy Approvals Mark Shifting Standards in Multiple Myeloma

June 13th 2024

Minoo Battiwalla, MD, MS, discusses the impact of earlier-line FDA approvals for CAR T-cell therapies on treatment outcomes in multiple myeloma.

Dr Neelapu on Streamlining the Delivery of CAR T-Cell Therapy in Lymphoma

June 12th 2024

Sattva S. Neelapu, MD, discusses processes that have been adopted to streamline the delivery of CAR T-cell therapy to patients with lymphoma.

Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas

June 11th 2024

Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma.

Braun Spotlights Novel Treatment Developments in RCC

June 10th 2024

David A. Braun, MD, PhD, highlights the developing role of T-cell therapies in RCC and looks toward the horizon for other advances.

UCART22 Earns Orphan Drug Designation for Acute Lymphoblastic Leukemia in Europe

June 5th 2024

The European Commission granted orphan drug designation to UCART22 for acute lymphoblastic leukemia.

OncLive’s May Roundup of Key FDA Approvals in Oncology

May 31st 2024

Here is your guide to important regulatory approvals made by the FDA in May 2024.

FDA Approves Liso-Cel for R/R Mantle Cell Lymphoma After 2 Lines of Therapy

May 30th 2024

The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a BTK inhibitor.

CT041 Shows Tolerability and Early Efficacy in Refractory Metastatic Pancreatic Cancer

May 29th 2024

CT041 was safe and showcased early signals of antitumor activity in heavily pretreated patients with metastatic pancreatic cancer.

Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma

May 24th 2024

James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.

CAR T-Cell Therapies Move Ahead in Pediatric and Adult ALL

May 22nd 2024

Carrie L. Kitko, MD, discusses the current standing of cellular therapies in adult and pediatric ALL and looks toward future developments.

Neelapu Highlights the Nuances of CAR T-Cell Therapy Administration in Lymphoma

May 20th 2024

Sattva S. Neelapu, MD, discusses the optimal processes of CAR T-cell therapy administration and the remaining unmet needs in the space.

WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL

May 20th 2024

WU-CART-007 has received RMAT and PRIME designations in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

CAR T-Cell Agents Offer Efficacy in Lymphoma, But Additional Approaches Are Needed to Overcome Resistance

May 17th 2024

Sattva S. Neelapu, MD, discusses the current standing of CAR T-cell therapies in the treatment paradigm in lymphoma.

FDA Grants Accelerated Approval to Liso-Cel for Relapsed/Refractory Follicular Lymphoma

May 15th 2024

The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.

Strategies to Improve CAR T-cell Durability in Lymphoma

May 15th 2024

Samuel Yamshon, MD, of Weill Cornell Medicine/NewYork-Presbyterian, discusses strategies to improve CAR T-cell durability in patients with non-Hodgkin lymphoma.

Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS

May 14th 2024

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

Dr Ignatz-Hoover on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma

May 14th 2024

James Ignatz-Hoover, MD, PhD discusses sequencing CAR T cell therapies and bispecific agents in treating pretreated patients with multiple myeloma.

Dr Jagannath on the Safety Considerations With CAR T-Cell Therapy Multiple Myeloma

May 10th 2024

Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.

Earlier CAR T Use in Multiple Myeloma: Game Changer or Boutique Medicine?

May 7th 2024

Krina K. Patel, MD, MSc, discusses her thoughts on moving CAR T-cell therapy up in the lines of treatment for patients with multiple myeloma.

Dr Oluwole on the Use of CAR T-Cell Therapy in Autoimmune Disorders

May 2nd 2024

Olalekan O. Oluwole, MBBS, MD, discusses the feasibility of using CAR T-cell therapy in patients with nonhematologic autoimmune disorders.